 DUBAI, UAE, June 3, 2021 PRNewswire -- Healthcare solutions provider Global Response Aid GRA today reported seven-month global sales figures for its anti-viral tablet AviganReeqonusTM, a drug being used in several countries to treat patients with mild to moderate cases of COVID-19. Over the course of a year, GRA has signed a global licensing agreement for Avigan with its developer, FujiFilm Toyama, filed a drug dossier with various regulators, and recently initiated a global Phase 3 clinical trial in an outpatient setting, said GRA CEO Mitch Wilson. 